Sofia Aakko

机构：Faron Pharmaceutical (Finland) · ORCID：0000-0003-1330-9288

发表论文 22 篇 · 总被引 211 次 · h-index 6

代表论文

• Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia (2022 · Blood · 被引 132)
• MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells (2018 · Translational Oncology · 被引 29)
• Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia (2022 · Blood · 被引 10)
• Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial (2025 · The Lancet Haematology · 被引 9)
• Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition (2021 · Frontiers in Oncology · 被引 8)
• CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies (2025 · Scientific Reports · 被引 6)